Table 2.
Overall response rates (ORR) and ongoing responses in phase I–II trials with checkpoint inhibitors in metastatic breast cancer
| ER+/HER2− | TNBC | |||||
|---|---|---|---|---|---|---|
| n | ORR | Ongoing responses | n | ORR | Ongoing responses | |
| Pembrolizumab (anti-PD-1) | ||||||
| Keynote-012 (phase Ib; [58]) | – | – | – | 32a | 18% | 11% (>1 year) |
| Keynote-086 (phase II) cohort A [60] | – | – | – | 170 | 5% | 0% |
| Keynote-086 (phase II) cohort B [59] | – | – | – | 52a | 23% | 29% (>1 year) |
| Keynote-028 (phase Ib; [61]) | 25a | 12% | 0% | – | – | – |
| Atezolizumab (anti-PD-L1) | ||||||
| Schmid P. (phase Ia; [62]) | – | – | – | 112 | 17% | n.g. |
| Avelumab (anti-PD-L1) | ||||||
| JAVELIN (phase Ib; [65]) | 72 | 3% | 4% (overall) | 58 | 5% | 4% (overall) |
ER+/HER2- hormone receptor positive, HER2-negative, TNBC triple negative breast cancer, n number of patients, ORR overall response rate, n.g. not given
aSelected for PD-L1+